Catalent Announces Clinical Trial Planning Service

Article

Catalent’s planning service is designed to assist in evaluating needs for launching and maintaining clinical trials.

Catalent announced the launch of the CTSuccess clinical trial planning service that uses a proprietary evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics.

The StartScore model is based on actual performance data which generates a risk-based score to help sponsors understand the appropriate level of clinical supply management oversight needed to start a project on time and maintain momentum as the study progresses, the company reported in a Dec. 12, 2019 press announcement.

“No two studies are the same, and each carries its own unique risks and presents individual challenges, but the aim of CTSuccess is to use the experience we have as a company in supplying materials for thousands of trials to identify the characteristics of a project upfront and highlight potential risk factors that may arise,” commented Kristen Devito, global director, Catalent Clinical Supply Services in the press statement. “Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.”

The company’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe, and Asia, and more than 50 depots around the world. The facilities provide local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management, the company reports.

Source: Catalent

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content